

GLAXOSMITHKLINE PLC
Form 6-K
May 09, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending May 2012

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
9 May 2012

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 4,444,541
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 15,000,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 5,353,854
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 14,090,687

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Share Option Plan - ADS
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 3,247,706
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 15,000,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 12,710,138
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 5,537,568

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: Glaxo Wellcome UK Share Option Scheme
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 5,119,750
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has

been applied for):

Less: Number of securities issued/allotted under scheme(s) 0
during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted at 5,119,750
end of period:

Name of contact: Victoria Whyte

Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of
applicant

GlaxoSmithKline plc

:

Name of scheme:

Glaxo Wellcome International Share Option Scheme

Period of return:

From:

1 November 2011

To:

30 April 2012

Balance of unallotted securities under scheme(s) from
previous return:

13,267,156

Plus: The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase 0
has been applied for):

Less: Number of securities issued/allotted under scheme(s) 0
during period (see LR3.5.7G):

Equals: Balance under scheme(s) not yet issued/allotted at 13,267,156
end of period:

Name of contact: Victoria Whyte

Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: Glaxo Wellcome 1999 Share Option Plan
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 1,040,000
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has 0 been applied for):
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals:
Balance under scheme(s) not yet issued/allotted at end of period: 1,040,000

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of applicant : GlaxoSmithKline plc
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 163,606
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 163,606

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 275,420
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
275,420

Equals: Balance under scheme(s) not yet issued/allotted at
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: SmithKline Beecham 1989 Executive Share Option
Plan - Unapproved - Ordinary
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from
previous return: 100,000
Plus: The amount by which the block scheme(s) has been
increased since the date of the last return (if any increase 0
has been applied for):
Less: Number of securities issued/allotted under scheme(s) 0
during period (see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at 100,000
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 9 May 2012

Name of applicant : GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline Savings Related Share Option Scheme
Period of return: From: 1 November 2011 To: 30 April 2012
Balance of unallotted securities under scheme(s) from previous return: 7,793,416
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 3,787,708
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 4,005,708

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 09, 2012

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc